15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

Drugs

Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog!

Collagenase clostridium histolyticum

Watch 0
Star 0

Identification

Pharmacology
Summary Collagenase clostridium histolyticum is a collagenase enzyme used to promote debridement of
Interactions necrotic tissue in burns and skin ulcers as well as to treat Dupuytren's contracture and Peyronie's
Products disease.

Categories
Brand Names Qwo, Santyl, Xiaflex
Chemical Identifiers

References Generic Name Collagenase clostridium histolyticum

Clinical Trials
DrugBank Accession Number DB00048
Pharmacoeconomics

Properties Background Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium
histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of
Targets (3) Dupuytren's contracture and Peyronie's disease.11 The topical formulation is used for the
debridement of necrotic tissue due to burns or chronic ulcers.14

On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for
the treatment of cellulite in adult women.10 Also known as Qwo, this injection is the first
approved injectable treatment for cellulite and was developed by Endo International.13

Type Biotech

Groups Approved, Investigational

Biologic Classification Protein Based Therapies

Other protein based therapies

Protein Structure

Protein Chemical Formula C5028H7666N1300O1564S21

Protein Average Weight 112023.2 Da

Sequences > Collagenase Sequence

MKRKCLSKRLMLAITMATIFTVNSTLPIYAAVDKNNATAAVQNESKRYTVSYLKTLNYYD

LVDLLVKTEIENLPDLFQYSSDAKEFYGNKTRMSFIMDEIGRRAPQYTEIDHKGIPTLVE

VVRAGFYLGFHNKELNEINKRSFKERVIPSILAIQKNPNFKLGTEVQDKIVSATGLLAGN

ETAPPEVVNNFTPILQDCIKNIDRYALDDLKSKALFNVLAAPTYDITEYLRATKEKPENT

PWYGKIDGFINELKKLALYGKINDNNSWIIDNGIYHIAPLGKLHSNNKIGIETLTEVMKV

YPYLSMQHLQSADQIKRHYDSKDAEGNKIPLDKFKKEGKEKYCPKTYTFDDGKVIIKAGA

RVEEEKVKRLYWASKEVNSQFFRVYGIDKPLEEGNPDDILTMVIYNSPEEYKLNSVLYGY

DTNNGGMYIEPEGTFFTYEREAQESTYTLEELFRHEYTHYLQGRYAVPGQWGRTKLYDND

RLTWYEEGGAELFAGSTRTSGILPRKSIVSNIHNTTRNNRYKLSDTVHSKYGASFEFYNY

ACMFMDYMYNKDMGILNKLNDLAKNNDVDGYDNYIRDLSSNYALNDKYQDHMQERIDNYE

NLTVPFVADDYLVRHAYKNPNEIYSEISEVAKLKDAKSEVKKSQYFSTFTLRGSYTGGAS

KGKLEDQKAMNKFIDDSLKKLDTYSWSGYKTLTAYFTNYKVDSSNRVTYDVVFHGYLPNE

GDSKNSLPYGKINGTYKGTEKEKIKFSSEGSFDPDGKIVSYEWDFGDGNKSNEENPEHSY

DKVGTYTVKLKVTDDKGESSVSTTTAEIKDLSENKLPVIYMHVPKSGALNQKVVFYGKGT

YDPDGSIAGYQWDFGDGSDFSSEQNPSHVYTKKGEYTVTLRVMDSSGQMSEKTMKIKITD

PVYPIGTEKEPNNSKETASGPIVPGIPVSGTIENTSDQDYFYFDVITPGEVKIDINKLGY

GGATWVVYDENNNAVSYATDDGQNLSGKFKADKPGRYYIHLYMFNGSYMPYRINIEGSVG

Download FASTA Format

Synonyms Clostridiopeptidase A Clostridium histolyticum enzymes Collagenase Collagenase clostridium histolyticum

View As Table
collagenase clostridium histolyticum-aaes

External IDs AA-4500 AA4500 PF-5076985

View As Table

PHARMACOLOGY

Indication Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's
contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease
diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of
therapy in addition to palpable plaques.11 Collagenase ointment is used for the tissue
debridement of chronic dermal ulcers and severely burned tissues.15
The combination
collagenase product, also known as Qwo, is used for the treatment of moderate to severe cellulite
in the buttocks of adult women.10

https://go.drugbank.com/drugs/DB00048 1/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

Build, train, & validate predictive machine-learning models with structured SEE HOW
datasets.

Drugs
Associated Conditions Dupuytren's Contracture of the Hand (Viking's Disease)
View As List
Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog!
Peyronie's Disease

Necrotic tissue

Contraindications & Blackbox

Avoid life-threatening adverse drug events & improve clinical decision
Warnings LEARN MORE
support.

Pharmacodynamics Collagenase digests collagen, treating conditions such as Peyronie's disease, cellulite, chronic
ulcers, burns, and contractures.10,11,14

Mechanism of action
Peyronie's disease is a fibrous lesion of the tunica albuginea in the penile tissues.4 Cellulite is a
multifactorial condition resulting in the accumulation of fibrotic dermal septae and the expansion
of subcutaneous fat.3 Dupuytren's contracture is a fibroproliferative disease that results in the
fibrous deposition of collagen in the hands, limiting mobility and functionality of the hands.5 The
collagen deposition in the abovementioned conditions is the target of collagenase enzyme
therapy.6,7

These enzymes are proteinases acting to hydrolyze collagen's triple-helical conformation,

resulting in the lysis of collagen deposits and relief from the necrotic tissue and plaques
associated with several conditions.11,14 On a molecular level, collagenases cleave polypeptide
chains that make up the collagen triple helix structure at various loci, leading to solubilization
from the collagen fibril.8

TARGET ACTIONS ORGANISM

A Collagen alpha-1(I) chain binder Humans

A Collagen alpha-1(II) chain binder Humans

A Collagen alpha-1(III) chain binder Humans

Absorption There is currently limited readily available regarding the absorption of collagenase through the
skin.14
In a pharmacokinetic study, the serum concentrations of clostridium type I collagenase
(AUX-I) and clostridium type II collagenase (AUX-II) were measured. Both were detected under the
lower limit of quantitation of 5 ng/mL and 25 ng/mL, respectively, in volunteers administered one
dose of the collagenase histolyticum combination product, Qwo, at a dose of up to 3.36 mg in a
maximum of 4 body areas.10

Volume of distribution
There is no currently available information regarding the presence of collagenase in body fluids or
uptake by particular organs and passage through the blood-brain barrier.14 Systemic
pharmacokinetic studies evaluation volume of distribution have not been performed, however,
collagenase histolyticum is likely to have local degradative effects in the region of the application
without effects on the vasculature and elastic tissue.9

Protein binding There is no readily available information regarding the protein binding of collagenase.14

Metabolism No formal systemic metabolism studies have been performed with collagenase histolyticum.9

Route of elimination Not Available

Half-life Not Available

Clearance Clearance information for collagenase is not readily available.14

Adverse Effects
Improve decision support & research outcomes with our structured adverse
LEARN MORE
effects data.

Toxicity No clinical reaction has been attributed to an overdose of collagenase in clinical trials.14 If
required, the collagenase enzymes can be inactivated with a povidone-iodine wash.14

Pathways Not Available

Pharmacogenomic Effects/ADRs Not Available

INTERACTIONS

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are
experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does
not necessarily mean no interactions exist.

APPROVED VET APPROVED NUTRACEUTICAL ILLICIT WITHDRAWN INVESTIGATIONAL EXPERIMENTAL

ALL DRUGS

Show 10 entries

Search

https://go.drugbank.com/drugs/DB00048 2/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

DRUG ↑↓ INTERACTION ↑↓

INTEGRATE DRUG-DRUG INTERACTIONS IN YOUR SOFTWARE

Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Collagenase
Drugs
clostridium histolyticum.

Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog! Acenocoumarol The risk or severity of adverse effects can be increased when Acenocoumarol is combined with
Collagenase clostridium histolyticum.

Alteplase The risk or severity of adverse effects can be increased when Alteplase is combined with Collagenase
clostridium histolyticum.

Ancrod The risk or severity of adverse effects can be increased when Ancrod is combined with Collagenase
clostridium histolyticum.

Anistreplase The risk or severity of adverse effects can be increased when Anistreplase is combined with
Collagenase clostridium histolyticum.

Antithrombin Alfa The risk or severity of adverse effects can be increased when Antithrombin Alfa is combined with
Collagenase clostridium histolyticum.

Antithrombin III human The risk or severity of adverse effects can be increased when Antithrombin III human is combined with
Collagenase clostridium histolyticum.

Apixaban The risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase
clostridium histolyticum.

Ardeparin The risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase
clostridium histolyticum.

Argatroban The risk or severity of adverse effects can be increased when Argatroban is combined with Collagenase
clostridium histolyticum.

Showing 1 to 10 of 67 entries

‹ 1 2 3 4 5 6 7 ›

Food Interactions No interactions found.

PRODUCTS

Access drug product information from over 10 global regions. ACCESS NOW

International/Other Brands Cordase

Brand Name Prescription Products Show 10 entries

Search

MARKETING MARKETING
NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Collagenase Ointment 250 Topical Healthpoint 2006-10-18 2017-06-30

Santyl [arb'U]/1g

Collagenase Ointment 250 Topical SMITH & 2006-10-18 Not applicable

Santyl [arb'U]/1g NEPHEW, INC

Qwo Injection, powder, 0.23 mg/1mL Intralesional Endo Aesthetics 2021-02-01 Not applicable
lyophilized, for LLC
solution

Santyl Ointment 250 unit / g Topical Smith & Nephew, 1994-12-31 Not applicable
Inc.

Xiaflex Powder, for 0.9 mg / vial Intralesional Endo Ventures 2012-11-14 2020-06-11
solution Ltd

Xiaflex Injection, powder, 0.9 mg/1 Intralesional Endo 2010-02-22 Not applicable
lyophilized, for Pharmaceuticals
solution; Kit Inc.

Xiapex Injection, powder, 0.9 mg Intralesional Swedish Orphan 2016-09-08 2020-03-02

for solution Biovitrum Ab

Showing 1 to 7 of 7 entries

‹ 1 ›

Over the Counter Products Show 10 entries

Search

MARKETING MARKETING
NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

IRUXOL Ointment 1.2 IU Topical SMITH & NEPHEW 2020-09-08 Not applicable
MONO HEALTHCARE SDN BHD

Showing 1 to 1 of 1 entries

‹ 1 ›

Mixture Products Show 10 entries

Search

MARKETING MARKETING
NAME ↑↓ INGREDIENTS DOSAGE ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Kimchi Collagenase clostridium Tablet, Oral Tobico 2010-03-18 Not applicable

Vitamin histolyticum (5.625 mg/1) + chewable
Ascorbic acid (180 mg/1) +
chewable
Cholecalciferol (0.375 mg/1) +
multivitamin
Folic acid (0.03 mg/1) + Lactic
acid (30 mg/1) + Nicotinamide
https://go.drugbank.com/drugs/DB00048 3/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online
acid (30 mg/1) + Nicotinamide
(0.045 mg/1) + Pyridoxine (0.285 MARKETING MARKETING
NAME ↑↓ INGREDIENTS
mg/1) + Riboflavin (0.24 mg/1) + DOSAGE ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓
Thiamine chloride (0.195 mg/1) +
Vitamin A (0.675 mg/1) + Vitamin
Drugs
E (1.875 mg/1)

Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog! Showing 1 to 1 of 1 entries

‹ 1 ›

Unapproved/Other Products Show 10 entries

Search

MARKETING MARKETING
NAME ↑↓ INGREDIENTS DOSAGE ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Kimchi Collagenase clostridium Tablet, Oral Tobico 2010-03-18 Not applicable

Vitamin histolyticum (5.625 mg/1) + chewable
Ascorbic acid (180 mg/1) +
chewable
Cholecalciferol (0.375 mg/1) +
multivitamin
Folic acid (0.03 mg/1) + Lactic
acid (30 mg/1) + Nicotinamide
(0.045 mg/1) + Pyridoxine (0.285
mg/1) + Riboflavin (0.24 mg/1) +
Thiamine chloride (0.195 mg/1) +
Vitamin A (0.675 mg/1) + Vitamin
E (1.875 mg/1)

Showing 1 to 1 of 1 entries

‹ 1 ›

CATEGORIES

ATC Codes D03BA02 — Collagenase

D03BA — Proteolytic enzymes
D03B — ENZYMES
D03 — PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
D — DERMATOLOGICALS

M09AB02 — Collagenase clostridium histolyticum

M09AB — Enzymes
M09A — OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09 — OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M — MUSCULO-SKELETAL SYSTEM

D03BA52 — Collagenase, combinations

D03BA — Proteolytic enzymes
D03B — ENZYMES
D03 — PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
D — DERMATOLOGICALS

Drug Categories Collagen-specific Enzyme

Collagenases

Dermatologicals

Endopeptidases

Enzymes

Enzymes and Coenzymes

Hydrolases

Metalloendopeptidases

Metalloproteases

Microbial Collagenase, antagonists & inhibitors

Misc. Skin and Mucous Membrane Agents

Musculo-Skeletal System

Peptide Hydrolases

Preparations for Treatment of Wounds and Ulcers

Chemical Taxonomy Description Not Available

Provided by Classyfire
Kingdom Organic Compounds

Super Class Organic Acids

Class Carboxylic Acids and Derivatives

Sub Class Amino Acids, Peptides, and Analogues

Direct Parent Peptides

Alternative Parents Not Available

Substituents Not Available

Molecular Framework Not Available

External Descriptors Not Available

Affected organisms Humans and other mammals

https://go.drugbank.com/drugs/DB00048 4/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

CHEMICAL IDENTIFIERS

UNII 9X7O8V25IT Drugs

CAS
Learn to leverage the Clinical API: number Alternatives Read Blog!9001-12-1
Therapeutic

REFERENCES

Synthesis Reference Hun-Chi Lin, Shau-Ping Lei, "Molecular cloning of the genes responsible for collagenase
production from Clostridium histolyticum." U.S. Patent US5177017, issued December, 1972.
US5177017

General References
1. Norris DB, Trudgill PW: Multiple forms of cyclohexanone oxygenase from Nocardia globerula CL1. Eur J Biochem. 1976 Mar
16;63(1):193-8. [Article]
2. Pajot P: Fluroescence of proteins in 6-M guanidine hydrochloride. A method for the quantitative determination of tryptophan.
Eur J Biochem. 1976 Mar 16;63(1):263-9. [Article]
3. Rossi AM, Katz BE: A modern approach to the treatment of cellulite. Dermatol Clin. 2014 Jan;32(1):51-9. doi:
10.1016/j.det.2013.09.005. [Article]
4. Randhawa K, Shukla CJ: Non-invasive treatment in the management of Peyronie's disease. Ther Adv Urol. 2019 Feb
11;11:1756287218823671. doi: 10.1177/1756287218823671. eCollection 2019 Jan-Dec. [Article]
5. Grazina R, Teixeira S, Ramos R, Sousa H, Ferreira A, Lemos R: Dupuytren's disease: where do we stand? EFORT Open Rev. 2019
Feb 20;4(2):63-69. doi: 10.1302/2058-5241.4.180021. eCollection 2019 Feb. [Article]
6. Dhillon S: Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease. Drugs. 2015 Aug;75(12):1405-12. doi:
10.1007/s40265-015-0441-7. [Article]
7. Kaplan FT: Collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture. Drugs Today (Barc).
2011 Sep;47(9):653-67. doi: 10.1358/dot.2011.47.9.1656502. [Article]
8. Krane SM: Collagenases and collagen degradation. J Invest Dermatol. 1982 Jul;79 Suppl 1:83s-86s. doi: 10.1111/1523-
1747.ep12545849. [Article]
9. Andrew J Watt, Vincent R Hentz: Collagenase clostridium histolyticum: a novel nonoperative treatment for Dupuytren’s disease
Int. J. Clin. Rheumatol.. [Article]
10. FDA Approved Products: Qwo (collagenase clostridium histolyticum-aaes) for subcutaneous injection [Link]
11. FDA Approved Products: Ziaflex (collagenase clostridium histolyticum) for intralesional use [Link]
12. Thermo Fisher SDS: Collagenase, Type II Powder [Link]
13. Endo International website [Link]
14. FDA Approved Products: Santyl (collagenase) ointment [Link]
15. Product monograph: Santyl (collagenase) [Link]

External Links KEGG Compound C00816

PubChem Substance 46506485

RxNav 58939

Therapeutic Targets Database DAP000965

PharmGKB PA449107

RxList RxList Drug Page

Drugs.com Drugs.com Drug Page

Wikipedia Collagenase

MSDS Download (72.9 KB)

CLINICAL TRIALS

Clinical Trials Show 10 entries

Search

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓

4 Active Not Recruiting Treatment Dupuytren's Contracture of the Hand (Viking's Disease) 1

4 Active Not Recruiting Treatment Dupuytren's Disease of Finger 1

4 Active Not Recruiting Treatment Peyronie's Disease 1

4 Completed Basic Science Impaired Wound Healing / Scarring 1

4 Completed Diagnostic Diabetic Foot Ulcers (DFUs) 1

4 Completed Treatment Diabetic Foot Ulcers (DFUs) 1

4 Completed Treatment Diabetic Foot Ulcers (DFUs) / Diabetic Foot Wounds 3

4 Completed Treatment Diabetic Foot Ulcers (DFUs) / Wound; Foot 1

4 Completed Treatment Diabetic Foot / Diabetic Foot Ulcers (DFUs) 1

4 Completed Treatment Dupuytren's Contracture of the Hand (Viking's Disease) 4

Showing 1 to 10 of 58 entries

‹ 1 2 3 4 5 6 ›

PHARMACOECONOMICS

Manufacturers Not Available

Packagers Abbott Laboratories Ltd.

Advance Biofactures Corp.

Auxilium Pharmaceuticals

BASF Corp.

Dispensing Solutions

https://go.drugbank.com/drugs/DB00048 5/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

Healthpoint Ltd.

Medisca Inc.

Drugs
Dosage Forms Show 10 entries

Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog!

Search

FORM ↑↓ ROUTE ↑↓ STRENGTH ↑↓

Ointment Topical 250 [arb'U]/1g

Ointment Topical

Ointment Topical 120 IU

Ointment Topical 1.2 IU

Ointment Topical 1.2 u/g

Tablet, chewable Oral

Injection, powder, lyophilized, for solution Intralesional 0.23 mg/1mL

Ointment Topical 250 unit / g

Ointment Topical

Injection, powder, lyophilized, for solution; kit Intralesional 0.9 mg/1

Showing 1 to 10 of 14 entries

‹ 1 2 ›

Prices Show 10 entries

Search

UNIT DESCRIPTION ↑↓ COST ↑↓ UNIT ↑↓

Xiaflex 0.9 mg vial 3900.0USD vial

Collagenase powder 2432.7USD g

Santyl 250 unit/gm Ointment 15 gm Tube 62.98USD tube

Santyl ointment 4.13USD g

Showing 1 to 4 of 4 entries

‹ 1 ›

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents Not Available

PROPERTIES

State Solid

Experimental Properties PROPERTY VALUE SOURCE

melting point (°C) 49-54 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406112/

hydrophobicity -0.714 Not Available

isoelectric point 5.35-6.20 https://pubs.acs.org/doi/pdfplus/10.1021/bi00308a036?src=recsys

TARGETS

Use our structured and evidence-based datasets to unlock new insights

LEARN MORE
and accelerate drug research.

1. Collagen alpha-1(I) chain Details

Kind Protein

Organism Humans

Pharmacological action Yes

Actions Binder

Curator comments Collagenase targets many types of collagen chains. This chain has been selected as a
representative collagen chain, though others may also be targeted.

General Function Platelet-derived growth factor binding

Specific Function Type I collagen is a member of group I collagen (fibrillar forming collagen).

Gene Name COL1A1

Uniprot ID P02452

Uniprot Name Collagen alpha-1(I) chain

Molecular Weight 138941.105 Da

References

1. Egeblad M, Shen HC, Behonick DJ, Wilmes L, Eichten A, Korets LV, Kheradmand F, Werb Z, Coussens LM: Type I collagen is a genetic modifier of matrix
metalloproteinase 2 in murine skeletal development. Dev Dyn. 2007 Jun;236(6):1683-93. [Article]

https://go.drugbank.com/drugs/DB00048 6/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online
2. Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RT: Effect of a cleavage-resistant collagen mutation on
left ventricular remodeling. Circ Res. 2003 Aug 8;93(3):238-45. Epub 2003 Jul 10. [Article]
3. Beare AH, O'Kane S, Krane SM, Ferguson MW: Severely impaired wound healing in the collagenase-resistant mouse. J Invest Dermatol. 2003 Jan;120(1):153-63. [Article]
4. Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis.
Drugs
Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. [Article]
5. Beare AH, Krane SM, Ferguson MW: Variable impairment of wound healing in the heterozygous collagenase-resistant mouse. Wound Repair Regen. 2005 Jan-
Learn to leverage the Clinical API: Therapeutic Alternatives
Feb;13(1):27-40. [Article] Read Blog!

2. Collagen alpha-1(II) chain Details

Kind Protein

Organism Humans

Pharmacological action Yes

Actions Binder

Curator comments Collagenase targets many types of collagen chains. This chain has been selected as a
representative collagen chain, though others may also be targeted.

General Function Platelet-derived growth factor binding

Specific Function Type II collagen is specific for cartilaginous tissues. It is essential for the normal
embryonic development of the skeleton, for linear growth and for the ability of
cartilage to resist compressiv...

Gene Name COL2A1

Uniprot ID P02458

Uniprot Name Collagen alpha-1(II) chain

Molecular Weight 141785.08 Da

References

1. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the
onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003 Nov;48(11):3085-95. [Article]
2. Imai K, Dalal SS, Hambor J, Mitchell P, Okada Y, Horton WC, D'Armiento J: Bone growth retardation in mouse embryos expressing human collagenase 1. Am J Physiol
Cell Physiol. 2007 Oct;293(4):C1209-15. Epub 2007 Jul 25. [Article]
3. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP: Radiographic joint damage in rheumatoid arthritis is associated
with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther. 2006;8(1):R31.
Epub 2006 Jan 10. [Article]
4. Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP: Articular chondrocytes cultured in hypoxia: their response to interleukin-1beta and rhein, the active
metabolite of diacerhein. Biorheology. 2004;41(3-4):549-61. [Article]
5. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic
cleavage. J Biol Chem. 2003 Nov 14;278(46):45539-45. Epub 2003 Jul 30. [Article]

3. Collagen alpha-1(III) chain Details

Kind Protein

Organism Humans

Pharmacological action Yes

Actions Binder

Curator comments Collagenase targets many types of collagen chains. This chain has been selected as a
representative collagen chain, though others may also be targeted.

General Function Platelet-derived growth factor binding

Specific Function Collagen type III occurs in most soft connective tissues along with type I collagen.
Involved in regulation of cortical development. Is the major ligand of GPR56 in the
developing brain and binding...

Gene Name COL3A1

Uniprot ID P02461

Uniprot Name Collagen alpha-1(III) chain

Molecular Weight 138564.005 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
3. Cole WG, Chiodo AA, Lamande SR, Janeczko R, Ramirez F, Dahl HH, Chan D, Bateman JF: A base substitution at a splice site in the COL3A1 gene causes exon skipping
and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem. 1990 Oct 5;265(28):17070-7. [Article]

Drug created at June 13, 2005 13:24 / Updated at November 15, 2022 08:41

About Support Products

About DrugBank Online Help Center Commercial Drug Da

Blog DrugBank Online FAQs Academic Drug Data

https://go.drugbank.com/drugs/DB00048 7/8
15/11/22, 13:04 Collagenase clostridium histolyticum: Uses, Interactions, Mechanism of Action | DrugBank Online

Wishart Research Group Contact Support Clinical API

Careers Contact Sales

Stay up-to-date with the latest from Terms of Use Drugs

Privacy Policy
DrugBank!
Learn to leverage the Clinical API: Therapeutic Alternatives Read Blog!

Enter your email SUBSCRIBE

Website design by Educe Design & Innovation Inc.

https://go.drugbank.com/drugs/DB00048 8/8